pyrimidinones and Astrocytoma

pyrimidinones has been researched along with Astrocytoma* in 10 studies

Other Studies

10 other study(ies) available for pyrimidinones and Astrocytoma

ArticleYear
Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Journal of neurology, 2020, Volume: 267, Issue:3

    A patient who was initially considered to have a glioblastoma (GBM) had molecular analysis, showing that it was a pleomorphic xanthoastrocytoma (PXA). Up to 78% of PXA tumors have BRAF V600E mutations. Primary brain tumors with BRAF mutations can have a good response to BRAF MEK inhibitors (BRAF MEKi), and there may be a synergistic response when combined with autophagy inhibitors.. A 20-year-old man found to have a large brain mass with midline shift underwent resection. He was diagnosed with "GBM" and treated with radiation and temozolomide with subsequent disease recurrence. Review of histology showed malignant PXA with BRAF V600E mutation. Treatment with Dabrafenib and Trametinib was started, and tumor size increased in size after 14 months of treatment. Given studies showing that resistance to BRAF inhibition can be overcome by autophagy inhibition, chloroquine was added. Patient has been on "triple" therapy for 15 months and has radiographically Stable Disease. At MCC, 3% of patients with gliomas have BRAF mutations who could potentially benefit from this combination therapy.. This is the first report of a PXA patient receiving therapy with BRAF MEKi and an autophagy inhibitor with prolonged stable disease. This patient highlights the importance of a molecular interrogation in gliomas to provide an integrated diagnosis and effective treatment. This may be useful in up to 3% of glioma patients with BRAF mutations. Molecular testing in neuro-oncology is providing new avenues of diagnosis and treatment, and detailed molecular interrogation should be considered routine.

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chloroquine; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Oximes; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Young Adult

2020
Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
    Cell death & disease, 2020, 08-21, Volume: 11, Issue:8

    Diffuse intrinsic pontine gliomas (DIPG) are the most aggressive brain tumors in children with 5-year survival rates of only 2%. About 85% of all DIPG are characterized by a lysine-to-methionine substitution in histone 3, which leads to global H3K27 hypomethylation accompanied by H3K27 hyperacetylation. Hyperacetylation in DIPG favors the action of the Bromodomain and Extra-Terminal (BET) protein BRD4, and leads to the reprogramming of the enhancer landscape contributing to the activation of DIPG super enhancer-driven oncogenes. The activity of the acetyltransferase CREB-binding protein (CBP) is enhanced by BRD4 and associated with acetylation of nucleosomes at super enhancers (SE). In addition, CBP contributes to transcriptional activation through its function as a scaffold and protein bridge. Monotherapy with either a CBP (ICG-001) or BET inhibitor (JQ1) led to the reduction of tumor-related characteristics. Interestingly, combined treatment induced strong cytotoxic effects in H3.3K27M-mutated DIPG cell lines. RNA sequencing and chromatin immunoprecipitation revealed that these effects were caused by the inactivation of DIPG SE-controlled tumor-related genes. However, single treatment with ICG-001 or JQ1, respectively, led to activation of a subgroup of detrimental super enhancers. Combinatorial treatment reversed the inadvertent activation of these super enhancers and rescued the effect of ICG-001 and JQ1 single treatment on enhancer-driven oncogenes in H3K27M-mutated DIPG, but not in H3 wild-type pedHGG cells. In conclusion, combinatorial treatment with CBP and BET inhibitors is highly efficient in H3K27M-mutant DIPG due to reversal of inadvertent activation of detrimental SE programs in comparison with monotherapy.

    Topics: Acetylation; Astrocytoma; Azepines; Brain Stem Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; CREB-Binding Protein; Diffuse Intrinsic Pontine Glioma; Gene Expression Regulation, Neoplastic; Glioma; Histones; Humans; Mutation; Nuclear Proteins; Nucleosomes; Proteins; Pyrimidinones; Transcription Factors; Transcriptional Activation; Triazoles

2020
Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:1

    Topics: Antineoplastic Agents; Astrocytoma; Drug Resistance, Neoplasm; Humans; Infant; Male; Neurofibromatosis 1; Prognosis; Pyridones; Pyrimidinones; Remission Induction; Salvage Therapy

2019
Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Female; Humans; Imidazoles; Meningeal Carcinomatosis; Mutation; Oximes; Prognosis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones

2019
Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:6

    Pleomorphic xanthoastrocytoma is a rare brain tumor with unique high frequency of BRAF V600E mutation which is plausible for targeted therapy. The anaplastic variant has generally worse prognosis. We present an adolescent patient with a disseminated relapse of anaplastic pleomorphic xanthoastrocytoma following surgery, radiotherapy, and chemotherapy. She had a dramatic and prolonged response to a BRAF inhibitor (Dabrafinib) and later to addition of a MEK inhibitor (Trametinib) on tumor progression. With minimal side effects and a good quality of life, the patient is alive more than 2 years after initiation of targeted therapy. This experience confirms the potential role of targeted treatments in high-grade BRAF-mutated brain tumors.

    Topics: Adolescent; Amino Acid Substitution; Astrocytoma; Brain Neoplasms; Female; Humans; Imidazoles; Mutation, Missense; Oximes; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones

2018
Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y
    Journal of medicinal chemistry, 2018, 04-12, Volume: 61, Issue:7

    The human P2Y

    Topics: Astrocytoma; Cell Line; Dibenzocycloheptenes; Fluorescent Dyes; Humans; Ligands; Microscopy, Confocal; Molecular Probes; Protein Binding; Purinergic P2 Receptor Antagonists; Pyrimidinones; Receptors, Purinergic P2Y2; Recombinant Proteins; Structure-Activity Relationship

2018
Encephalocraniocutaneous Lipomatosis.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:7

    A 5-year-old boy presented with worsening headaches for 3 months. On examination, he was found to have a hairless fatty tissue nevus of the scalp (nevus psiloliparus), subcutaneous soft tissue masses on the right side of his face, neck, mandible and right buttock and epibulbar dermoid of the right eye (choristoma) (). Magnetic resonance imaging revealed a large suprasellar mass, which was debulked and found to be a pilocytic astrocytoma. Testing was not performed for the BRAF/KIAA1549 fusion or BRAFV600E mutation. Seven years later, he was started on adjuvant chemotherapy for gradual tumor progression. Over the ensuing 3 years, he had further disease progression despite treatment with 3 frontline chemotherapy regimens: vinblastine, carboplatin/vincristine, and irinotecan/bevacizumab. Targeted sequencing of tissue from the right gluteal mass, revealed a mosaic activating FGFR1 c.1966A>G (p.Lys656Glu) mutation, absent in normal left gluteal tissue, confirming the diagnosis of encephalocraniocutaneous lipomatosis (ECCL), belonging to the family of RASopathies (including neurofibromatosis type I, Noonan syndrome, Costello syndrome), with constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, and an increased risk of developing neoplasms. He was started on trametinib, a MEK inhibitor, off-label, targeting the MAPK pathway downstream from FGFR1, with stable tumor size at last follow-up, after 6 months on therapy.

    Topics: Astrocytoma; Child, Preschool; Disease Progression; Eye Diseases; Humans; Lipomatosis; Magnetic Resonance Imaging; Male; Mitogen-Activated Protein Kinases; Neurocutaneous Syndromes; Pyridones; Pyrimidinones; Receptor, Fibroblast Growth Factor, Type 1; Treatment Outcome

2018
Trametinib for progressive pediatric low-grade gliomas.
    Journal of neuro-oncology, 2018, Volume: 140, Issue:2

    Pediatric pilocytic astrocytomas (PAs) are low grade gliomas and the most common brain tumors in children. They often represent a therapeutic challenge when incompletely resected as they can recur and progress despite the use of several lines of chemotherapeutic agents or even radiation therapy. Genetic alterations leading to activation of the mitogen-activated-protein-kinase pathway are a hallmark of this disease and offer an interesting therapeutic alternative through the use of targeted inhibitors.. Here, we describe six children with sporadic PA who were treated with trametinib, a MEK inhibitor, following progression under conventional therapies. Retrospective chart review was performed.. The median age at diagnosis was 2.3 years (y) old [range 11 months (m)-8.5 y old]. KIAA1549-BRAF fusion was identified in five cases, and hotspot FGFR1/NF1/PTPN11 mutations in one. All patients received at least one previous line of chemotherapy (range 1-4). The median time on treatment was 11 m (range 4-20). Overall, we observed two partial responses and three minor responses as best response; three of these patients are still on therapy. Treatment was discontinued in the patient with progressive disease. The most frequent toxicities were minor to moderately severe skin rash and gastro-intestinal symptoms. Two patients had dose reduction due to skin toxicity. Quality of life was excellent with decreased hospital visits and a close to normal life.. Trametinib appears to be a suitable option for refractory pediatric low-grade glioma and warrants further investigations in case of progression.

    Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Disease Progression; Female; Humans; Infant; Male; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Retreatment; Retrospective Studies

2018
Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response.
    Journal of neurosurgery. Pediatrics, 2017, Volume: 19, Issue:3

    Brain tumors are the most common solid tumor in childhood, and astrocytomas account for the largest proportion of these tumors. Increasing sophistication in genetic testing has allowed for the detection of specific mutations within tumor subtypes that may represent targets for individualized tumor treatment. The mitogen-activating protein kinase (MAPK) pathway and, more specifically, BRAF mutations have been shown to be prevalent in pediatric pilocytic astrocytomas and may represent one such area to target. Herein, the authors describe 2 cases of inoperable, chemotherapy-resistant pediatric pilocytic astrocytomas with a documented response to trametinib, an MAPK pathway inhibitor. While these cases were not treated in the setting of a clinical trial, their data support further ongoing clinical trial investigation to evaluate the safety and efficacy of this agent in pediatric low-grade gliomas.

    Topics: Antineoplastic Agents; Astrocytoma; Child, Preschool; Disease Progression; Female; Humans; Hypothalamic Neoplasms; Infant; Optic Nerve Neoplasms; Organ Size; Pyridones; Pyrimidinones; Treatment Outcome

2017
[2'-deoxyribosyl-4-amino-2-pyrimidone-5'-phosphate amino-hydrolase in some tumors of the human central nervous system].
    Bollettino della Societa italiana di biologia sperimentale, 1962, Dec-31, Volume: 38

    Topics: Aminohydrolases; Astrocytoma; Central Nervous System; Glioblastoma; Humans; Meningeal Neoplasms; Meningioma; Neoplasms; Phosphates; Pyrimidinones

1962